Article Information
History
- July 3, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Subotheni Thavaneswaran1,2,3,*,
- Frank P Lin2,3,4,
- Maya Kansara1,3,
- John P Grady1,
- David Espinoza2,
- Anthony M Joshua1,3,
- Peter Grimison5,
- Paul Craft6,
- Rasha Cosman1,3,
- Chee Lee2,
- Kathleen Harwood2,
- Sarah Chinchen2,
- Theresa Corpuz1,
- Mandy Ballinger1,3,
- Lucille Sebastian2,
- John Simes2 and
- David Thomas1,3
- 1The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, NSW, Australia
- 2NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia
- 3School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Australia
- 4Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Sydney, NSW, Australia
- 5Chris O’Brien Lifehouse, Camperdown, NSW, Australia
- 6The Canberra Hospital, ANU Medical School. Canberra, ACT, Australia
- ↵* Corresponding author; email: s.thavaneswaran{at}garvan.org.au
Posted July 03, 2022.
A signal-seeking Phase II trial of Durvalumab and Tremelimumab Focused on Advanced, Rare and Less Common Cancers
